Aurelio Maggio: Is It Time to Align Thalassemia Biology with Regulatory Science?
Aurelio Maggio, President of Foundation Franco and Piera Cutino, shared on LinkedIn:
”A Century After Cooley: Is It Time to Align Thalassemia Biology with Regulatory Science?
March 18–21, 2027 | Palermo, Italy
International GRADE-Based Consensus Conference
GARDEN Network – Global Hematological Rare Diseases Alliance
In 1925, Thomas Benton Cooley described what he called ‘Erythroblastic Anemia’, recognizing a profound disturbance in erythroid development.
More than a century later, thalassemia remains primarily classified as a globin gene disorder.
That molecular basis remains central.
However, translational evidence is expanding the framework.
Dysregulated hematopoietic stem cell (HSC) biology.
Persistent stress erythropoiesis. Metabolic hyperactivation. Epigenetic modulation.
These mechanisms appear to influence phenotypic heterogeneity, treatment responsiveness, disease-modifying potential, and long-term organ outcomes.
This is not a semantic issue. It is a regulatory one.
A stem cell–centered model could impact:
- Mechanism-based endpoint selection
- Biomarker qualification strategies
- Trial population stratification
- Surrogate endpoint validation
- Long-term follow-up architecture
In March 2027, we will convene the first international GRADE-based structured consensus to systematically assess this framework.
The goal is alignment — between biology, therapeutic innovation, and regulatory evaluation.
We welcome dialogue with regulatory authorities, HTA bodies, and industry partners interested in biologically coherent development strategies in rare hematologic diseases.
A century after its original description, reassessment may not be disruptive — it may be necessary.”
Stay updated with Hemostasis Today.
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026
-
Jul 12, 2026, 06:59Maaike Sybil Jongen: Flow Cytometry for Platelet Phenotyping at ISTH 2026